The California End of Life Option Act (EOLA), enacted in June 2016, provides terminally ill adult residents with the option to self-administer lethal drugs prescribed by a physician. Since its implementation, data has been collected to understand the utilization patterns and demographics of individuals choosing this option. This information offers valuable insights into who is accessing medical aid in dying in California, their age, health insurance
status, and engagement with palliative care services, painting a picture of the Act's real-world application.
Utilization Rates and Outcomes Since Inception
From the law's effective date on June 9, 2016, through December 31, 2023, a total of 6,516 individuals in California have been written prescriptions under the End of Life Option Act. Of this group, 4,287 individuals, which accounts for 66% of those who received prescriptions, died after ingesting the prescribed aid-in-dying medications. This indicates a consistent rate of utilization among those who obtain the prescriptions. The most recent data, covering the year 2023 and published in July 2024, shows that 1,281 individuals received prescriptions during that year. Of these, 884 individuals, or 69%, died following the ingestion of the prescribed drugs, a figure that includes 39 individuals who had received their prescriptions prior to 2023.
Demographic Profile of EOLA Participants
The demographic data for individuals utilizing the EOLA reveals several key characteristics. In 2023, a significant majority of those who died following the ingestion of aid-in-dying drugs were 60 years of age or older, specifically 92.8%. This suggests that the option is predominantly chosen by older adults facing terminal illnesses. Furthermore, the data indicates a high prevalence of health insurance coverage among participants, with 97.1% of individuals having health insurance. This could imply that access to comprehensive healthcare, including discussions about end-of-life options, plays a role in the decision-making process.
Another notable trend is the high rate of engagement with hospice and/or palliative care. In 2023, 93.8% of individuals who died after ingesting aid-in-dying medications were receiving hospice and/or palliative care. This suggests that the EOLA is often utilized as part of a broader end-of-life care plan, rather than as an isolated decision. The integration with hospice and palliative care indicates that patients are exploring various options for comfort and support as they approach the end of their lives, with medical aid in dying being one component of that comprehensive approach.
Broader Context of Medical Aid in Dying in the U.S.
California's experience with the End of Life Option Act is part of a larger movement across the United States concerning medical aid in dying. The state became the fifth to authorize such a practice, following others like Oregon, which passed the nation's first physician-assisted suicide law in 1994. The legal landscape for medical aid in dying has evolved significantly, with states like Colorado, Hawaii, Maine, New Jersey, and New Mexico also passing similar legislation. The consistent data collection in California, as seen in the annual reports, contributes to a growing body of knowledge about the practical application and impact of these laws, informing ongoing discussions about patient autonomy and end-of-life care across the nation.
